{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:33:07Z","timestamp":1793075587976,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020424","name":"Weill Cornell Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020424","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofliquidbiopsy.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Liquid Biopsy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jlb.2026.100667","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:11:00Z","timestamp":1790784660000},"page":"100667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["HER2 phenotyping of CTCs in breast cancer: a comparison across the spectrum of tissue HER2 expression level"],"prefix":"10.1016","volume":"14","author":[{"given":"Elisabetta","family":"Molteni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Foffano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3363-8512","authenticated-orcid":false,"given":"Letizia","family":"Pontolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Nicol\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenno","family":"Past\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Guimaraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Bayou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara Serena","family":"Serafini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Gianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Andreopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Gradishar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Cristofanilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Gerratana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Reduzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jlb.2026.100667_bib1","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ctrv.2011.11.005","article-title":"Molecular biology in breast cancer: intrinsic subtypes and signaling pathways","volume":"38","author":"Eroles","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.jlb.2026.100667_bib2","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.jlb.2026.100667_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jlb.2026.100667_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2023.100117","article-title":"Real-time assessment of HER2 status in circulating tumor cells of breast cancer patients: methods of detection and clinical implications","volume":"2","author":"Nicol\u00f2","year":"2023","journal-title":"J Liq Biopsy"},{"issue":"1","key":"10.1016\/j.jlb.2026.100667_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-022-00434-w","article-title":"HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment","volume":"8","author":"Miglietta","year":"2022","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.jlb.2026.100667_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113920","article-title":"Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer","volume":"201","author":"Tarantino","year":"2024","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.jlb.2026.100667_bib7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41416-023-02287-x","article-title":"Anticipating changes in the HER2 status of breast tumours with disease Progression\u2014towards better treatment decisions in the new era of HER2-low breast cancers","volume":"129","author":"Bergeron","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jlb.2026.100667_bib8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41523-021-00343-4","article-title":"Evolution of HER2-low expression from primary to recurrent breast cancer","volume":"7","author":"Miglietta","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.jlb.2026.100667_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejca.2021.12.022","article-title":"Evolution of low HER2 expression between early and advanced-stage breast cancer","volume":"163","author":"Tarantino","year":"2022","journal-title":"Eur J Cancer"},{"issue":"17","key":"10.1016\/j.jlb.2026.100667_bib10","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.3390\/cancers14174277","article-title":"Liquid biopsy, an everchanging balance between clinical utility and emerging technologies","volume":"14","author":"Cucciniello","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.jlb.2026.100667_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48501-x","article-title":"Liquid biopsy: from concept to clinical application","volume":"13","author":"Alix-Panabi\u00e8res","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jlb.2026.100667_bib12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1373\/clinchem.2019.303586","article-title":"Molecular and functional characterization of circulating tumor cells: from discovery to clinical application","volume":"66","author":"Cort\u00e9s-Hern\u00e1ndez","year":"2020","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.jlb.2026.100667_bib13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/gcc.22695","article-title":"Liquid biopsies","volume":"58","author":"Lianidou","year":"2019","journal-title":"Gene Chromosome Cancer"},{"key":"10.1016\/j.jlb.2026.100667_bib14","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/s41598-022-25400-1","article-title":"Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer","volume":"13","author":"Stergiopoulou","year":"2023","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.jlb.2026.100667_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/cells8060553","article-title":"Insights on CTC biology and clinical impact emerging from advances in capture technology","volume":"8","author":"Bailey","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.jlb.2026.100667_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2023.100132","article-title":"Cellular residual disease (CRD) in early breast cancer \u2013Expanding the concept of minimal residual disease monitoring?","volume":"3","author":"Serafini","year":"2024","journal-title":"J Liq Biopsy"},{"issue":"6","key":"10.1016\/j.jlb.2026.100667_bib17","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/1878-0261.12869","article-title":"Clinical utility of circulating tumor cells: an update","volume":"15","author":"Vasseur","year":"2021","journal-title":"Mol Oncol"},{"issue":"8","key":"10.1016\/j.jlb.2026.100667_bib18","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jlb.2026.100667_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.critrevonc.2018.12.004","article-title":"The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): international expert consensus paper","volume":"134","author":"Cristofanilli","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.jlb.2026.100667_bib20","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/clinchem\/hvad144","article-title":"Efficacy of lapatinib in patients with HER2-Negative metastatic breast cancer and HER2-Positive circulating tumor cells\u2014the DETECT III clinical trial","volume":"70","author":"Fehm","year":"2024","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.jlb.2026.100667_bib21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/s12935-025-04036-x","article-title":"Quantitative HER2 profiling on circulating tumor cells using an EpCAM-independent platform in metastatic breast cancer","volume":"25","author":"Bayou","year":"2025","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.jlb.2026.100667_bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13058-019-1229-6","article-title":"Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer","volume":"21","author":"Davis","year":"2019","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.jlb.2026.100667_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015624","article-title":"HER2-Positive circulating tumor cells in breast cancer","volume":"6","author":"Ignatiadis","year":"2011","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.jlb.2026.100667_bib24","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.3390\/cancers13102356","article-title":"Circulating tumor cell clusters are frequently detected in women with early-stage breast cancer","volume":"13","author":"Reduzzi","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.jlb.2026.100667_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186562","article-title":"Quantifying HER-2 expression on circulating tumor cells by ACCEPT","volume":"12","author":"Zeune","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jlb.2026.100667_bib26","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41391-020-00304-1","article-title":"Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer","volume":"24","author":"Oeyen","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.jlb.2026.100667_bib27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41416-021-01328-7","article-title":"Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression","volume":"125","author":"L\u00fc\u00f6nd","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jlb.2026.100667_bib28","series-title":"International review of cell and molecular biology","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/bs.ircmb.2023.07.003","article-title":"Chapter two - can we define breast cancer HER2 status by liquid biopsy?","volume":"vol. 381","author":"Di","year":"2023"},{"issue":"1","key":"10.1016\/j.jlb.2026.100667_bib29","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1016\/j.clbc.2018.10.009","article-title":"Detection of HER2-positive circulating tumor cells using the LiquidBiopsy system in breast cancer","volume":"19","author":"Chen","year":"2019","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"10.1016\/j.jlb.2026.100667_bib30","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10549-010-1163-x","article-title":"HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial","volume":"124","author":"Fehm","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"4_Supplement","key":"10.1016\/j.jlb.2026.100667_bib31","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS25-PS2-08-09","article-title":"Abstract PS2-08-09: Baseline HER2 expression on circulating tumor cells in metastatic breast cancer","volume":"32","author":"Past\u00f2","year":"2026","journal-title":"Clin Cancer Res"}],"container-title":["The Journal of Liquid Biopsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426002134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426002134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:00:16Z","timestamp":1793073616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950195426002134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":31,"alternative-id":["S2950195426002134"],"URL":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100667","relation":{},"ISSN":["2950-1954"],"issn-type":[{"value":"2950-1954","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2 phenotyping of CTCs in breast cancer: a comparison across the spectrum of tissue HER2 expression level","name":"articletitle","label":"Article Title"},{"value":"The Journal of Liquid Biopsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100667","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of The International Society of Liquid Biopsy.","name":"copyright","label":"Copyright"}],"article-number":"100667"}}